Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

• US 20030032632A1
• Filed: 06/24/2002
• Published: 02/13/2003
• Est. Priority Date: 12/24/1999
• Status: Abandoned Application

• Current Assignee: Smithkline Beecham Corporation (GlaxoSmithKline PLC)
• Original Assignee: Smithkline Beecham Corporation (GlaxoSmithKline PLC)
• Inventors: Paul, Johnson, Crispps, Leslie Alan
• Application Number:
  US10/168,672
• Publication Number:
  US 20030032632A1
• Time in Patent Office: Days
• US Class Current: 514/179
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics

Abstract

There is provided according to the invention a pharmaceutical aerosol formulation which comprises: (i) salmeterol or a pharmaceutically acceptable salt thereof, (ii) fluticasone propionate and (iii) a hydrofluoroalkane (HFA) propellant, characterized in that the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate are completely dissolved in the formulation.

Claims

28-1. Use of a pharmaceutical aerosol formulation according to any one of claims 1 to 31 in the manufacture of a medicament for the treatment of respiratory disorders, eg. asthma or chronic obstructive pulmonary disease (COPD).